vs
Pacira BioSciences, Inc.（PCRX）とRapid7, Inc.（RPD）の財務データ比較。上の社名をクリックして会社を切り替えられます
Rapid7, Inc.の直近四半期売上が大きい（$217.4M vs $196.9M、Pacira BioSciences, Inc.の約1.1倍）。Pacira BioSciences, Inc.の前年同期比売上増加率が高い（5.1% vs 0.5%）。Pacira BioSciences, Inc.の直近四半期フリーキャッシュフローが多い（$43.5M vs $36.4M）。過去8四半期でPacira BioSciences, Inc.の売上複合成長率が高い（8.5% vs 3.0%）
Pacira BioSciences社は非オピオイド系疼痛管理ソリューションの開発・商業化に特化した専門製薬企業で、主に米国の病院や外来手術センターなどの医療機関に術後鎮痛向け製品を提供し、一部海外市場への展開も進めています。
Rapid7社は世界的に有名なサイバーセキュリティ企業で、脆弱性管理、脅威検知・対応、クラウドセキュリティ、セキュリティ分析などの総合的なソリューションを提供しています。テクノロジー、医療、金融、製造業などの各業種の企業や公共部門を顧客とし、サイバー脅威への効率的な対応を支援します。
PCRX vs RPD — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $196.9M | $217.4M |
| 純利益 | — | $3.1M |
| 粗利率 | 79.5% | 68.9% |
| 営業利益率 | 1.2% | 1.0% |
| 純利益率 | — | 1.4% |
| 売上前年比 | 5.1% | 0.5% |
| 純利益前年比 | — | 44.1% |
| EPS（希薄化後） | $0.05 | $0.05 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $196.9M | $217.4M | ||
| Q3 25 | $179.5M | $218.0M | ||
| Q2 25 | $181.1M | $214.2M | ||
| Q1 25 | $168.9M | $210.3M | ||
| Q4 24 | $187.3M | $216.3M | ||
| Q3 24 | $168.6M | $214.7M | ||
| Q2 24 | $178.0M | $208.0M | ||
| Q1 24 | $167.1M | $205.1M |
| Q4 25 | — | $3.1M | ||
| Q3 25 | $5.4M | $9.8M | ||
| Q2 25 | $-4.8M | $8.3M | ||
| Q1 25 | $4.8M | $2.1M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | $-143.5M | $15.4M | ||
| Q2 24 | $18.9M | $6.5M | ||
| Q1 24 | $9.0M | $1.4M |
| Q4 25 | 79.5% | 68.9% | ||
| Q3 25 | 80.9% | 70.2% | ||
| Q2 25 | 77.4% | 70.6% | ||
| Q1 25 | 79.7% | 71.7% | ||
| Q4 24 | 78.7% | 69.5% | ||
| Q3 24 | 76.9% | 70.6% | ||
| Q2 24 | 75.1% | 70.7% | ||
| Q1 24 | 71.6% | 70.3% |
| Q4 25 | 1.2% | 1.0% | ||
| Q3 25 | 3.5% | 2.7% | ||
| Q2 25 | 4.7% | 1.6% | ||
| Q1 25 | 1.2% | -0.0% | ||
| Q4 24 | 13.2% | 3.4% | ||
| Q3 24 | -82.8% | 6.0% | ||
| Q2 24 | 15.9% | 2.5% | ||
| Q1 24 | 7.9% | 4.7% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | 3.0% | 4.5% | ||
| Q2 25 | -2.7% | 3.9% | ||
| Q1 25 | 2.8% | 1.0% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | -85.1% | 7.2% | ||
| Q2 24 | 10.6% | 3.1% | ||
| Q1 24 | 5.4% | 0.7% |
| Q4 25 | $0.05 | $0.05 | ||
| Q3 25 | $0.12 | $0.15 | ||
| Q2 25 | $-0.11 | $0.13 | ||
| Q1 25 | $0.10 | $0.03 | ||
| Q4 24 | $0.38 | $0.08 | ||
| Q3 24 | $-3.11 | $0.21 | ||
| Q2 24 | $0.39 | $0.09 | ||
| Q1 24 | $0.19 | $0.02 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $238.4M | $474.7M |
| 総負債低いほど良い | $372.2M | — |
| 株主資本純資産 | $693.1M | $154.7M |
| 総資産 | $1.3B | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | 0.54× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $238.4M | $474.7M | ||
| Q3 25 | $246.3M | $407.1M | ||
| Q2 25 | $445.9M | $511.7M | ||
| Q1 25 | $493.6M | $493.5M | ||
| Q4 24 | $484.6M | $521.7M | ||
| Q3 24 | $453.8M | $443.7M | ||
| Q2 24 | $404.2M | $442.6M | ||
| Q1 24 | $325.9M | $411.7M |
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $693.1M | $154.7M | ||
| Q3 25 | $727.2M | $127.2M | ||
| Q2 25 | $757.8M | $90.4M | ||
| Q1 25 | $798.5M | $52.7M | ||
| Q4 24 | $778.3M | $17.7M | ||
| Q3 24 | $749.6M | $-5.1M | ||
| Q2 24 | $879.3M | $-52.6M | ||
| Q1 24 | $892.2M | $-86.4M |
| Q4 25 | $1.3B | $1.7B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.5B | $1.6B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.7B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.6B | $1.5B | ||
| Q1 24 | $1.6B | $1.5B |
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $43.7M | $37.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $43.5M | $36.4M |
| FCFマージンFCF / 売上 | 22.1% | 16.8% |
| 設備投資強度設備投資 / 売上 | 0.1% | 0.5% |
| キャッシュ転換率営業CF / 純利益 | — | 12.01× |
| 直近12ヶ月FCF直近4四半期 | $136.7M | $146.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $43.7M | $37.6M | ||
| Q3 25 | $60.8M | $39.0M | ||
| Q2 25 | $12.0M | $47.5M | ||
| Q1 25 | $35.5M | $29.8M | ||
| Q4 24 | $33.1M | $63.8M | ||
| Q3 24 | $53.9M | $44.0M | ||
| Q2 24 | $53.2M | $32.9M | ||
| Q1 24 | $49.1M | $31.1M |
| Q4 25 | $43.5M | $36.4M | ||
| Q3 25 | $57.0M | $34.8M | ||
| Q2 25 | $9.3M | $46.6M | ||
| Q1 25 | $26.9M | $28.4M | ||
| Q4 24 | $31.0M | $62.6M | ||
| Q3 24 | $49.8M | $42.6M | ||
| Q2 24 | $51.6M | $32.6M | ||
| Q1 24 | $46.3M | $30.4M |
| Q4 25 | 22.1% | 16.8% | ||
| Q3 25 | 31.7% | 16.0% | ||
| Q2 25 | 5.1% | 21.8% | ||
| Q1 25 | 15.9% | 13.5% | ||
| Q4 24 | 16.6% | 28.9% | ||
| Q3 24 | 29.6% | 19.9% | ||
| Q2 24 | 29.0% | 15.7% | ||
| Q1 24 | 27.7% | 14.8% |
| Q4 25 | 0.1% | 0.5% | ||
| Q3 25 | 2.2% | 1.9% | ||
| Q2 25 | 1.5% | 0.4% | ||
| Q1 25 | 5.1% | 0.6% | ||
| Q4 24 | 1.1% | 0.5% | ||
| Q3 24 | 2.4% | 0.6% | ||
| Q2 24 | 0.9% | 0.1% | ||
| Q1 24 | 1.7% | 0.3% |
| Q4 25 | — | 12.01× | ||
| Q3 25 | 11.20× | 3.97× | ||
| Q2 25 | — | 5.70× | ||
| Q1 25 | 7.37× | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | — | 2.85× | ||
| Q2 24 | 2.82× | 5.03× | ||
| Q1 24 | 5.47× | 22.10× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
